Increasing evidence indicates that microbial communities in the gut and oral cavity can shape systemic immunity and influence central nervous system physiology. The source review frames these interactions through the gut–oral–brain axis, proposing mechanisms by which distant microbes and microbial metabolites may alter the brain tumour microenvironment. The article notes distinct gut and oral microbial signatures associated with patients who have primary or metastatic brain tumours. It also presents a conceptual figure illustrating pathways for microbial and metabolite transit from the oral cavity and gut to the central nervous system and tumour immune compartments.
The review highlights that microbes can modulate immune responses systemically, which in turn may affect tumour-associated immune landscapes in the brain. Specific mechanistic details, such as individual microbial taxa or metabolites mediating these effects in humans, were summarized from the literature but not exhaustively listed in the source preview.
Emerging clinical data summarized in the review indicate that some primary and metastatic brain tumours can contain intracellular microbial elements. The authors present a figure depicting intratumoural bacterial elements and their possible localization within tumour cells or immune cells. The review emphasizes that detection of microbes within tumour tissue has been reported, but the preview does not provide comprehensive prevalence estimates, specific taxa consistently found, or the clinical correlates of intratumoural presence.
The source cautions that claims of intratumoural microbes require careful validation because brain tumour tissues are low-biomass samples and therefore highly susceptible to contamination and technical artefacts. Where discussed, methods for confirming intratumoural presence—such as orthogonal imaging, culture, and nucleic acid-based validation—are advocated, but detailed protocols were not included in the accessible portion of the review.
Preclinical studies summarized in the review show that modulation of the gut microbiota can influence brain tumour growth and treatment responses in animal models. Examples cited in the source include work indicating that glioma and chemotherapy (temozolomide) can induce alterations in the gut microbiome, and that gut microbiota can mediate individualized efficacy of temozolomide via immunomodulatory mechanisms in experimental systems.
The review also references studies in which microbiome alterations affected tumor immune features such as regulatory T cell (Foxp3) expression within the tumour microenvironment in mice. Collectively, these preclinical data support a model in which the microbiota impacts antitumour immunity and therapeutic efficacy, though the preview does not supply quantitative effect sizes or standardized translational endpoints.
A prominent theme of the review is the substantial technical challenge of studying microbial signatures in brain tumours. The authors underscore low microbial biomass and a high risk of contamination as central obstacles that can confound sequencing and culture-based studies. They call for rigorous experimental design and standardized methodologies spanning clinical sampling, laboratory processing and computational analysis to minimize false-positive findings.
Specific recommendations described at a conceptual level include careful contamination controls, orthogonal validation of microbial signals (for example, combining sequencing with imaging or culture where possible), and computational approaches to distinguish true intratumoural signals from background noise. The source abstract and preview emphasize the need for community standards but do not present a detailed protocol or checklist within the accessible text.
The review identifies multiple translational opportunities arising from the interplay between the microbiota and brain tumours. Potential avenues include:
Modulating gut or oral microbiota to enhance therapeutic responses or mitigate treatment-related dysbiosis; preclinical evidence suggests this could affect chemotherapy efficacy.
Developing microbial signatures as biomarkers to inform prognosis or predict treatment response, subject to validation in robust clinical cohorts.
Investigating intratumoural microbial elements as therapeutic targets or as contributors to tumour biology; however, clinical implications are contingent on reproducible detection and causal demonstration.
The authors emphasize that moving toward clinical impact will require standardized study designs, reproducible methods for low-biomass microbiology, and rigorous translational studies bridging preclinical findings with human data. The previewed article presents figures and numerous references supporting these points but does not include exhaustive clinical trial data or validated clinical protocols in the accessible portion.
This Review synthesizes current knowledge linking the gut–oral–brain axis, systemic and intratumoural microbes, and brain tumour biology and treatment response. It highlights preclinical evidence that microbiota modulation can influence tumour growth and therapy, reports emerging clinical observations of intratumoural microbial elements, and stresses substantial technical and methodological challenges inherent to studies of brain tumour microbiology. The review concludes by outlining translational opportunities and calling for standardized, rigorous approaches to advance the field toward clinical application. Details such as prevalence rates, specific microbial taxa consistently implicated, and standardized experimental protocols were not reported in the source preview.